In a 109‑kg (BMI 35) male with multiple myeloma receiving daratumumab‑bortezomib‑dexamethasone, type 2 diabetes, normal renal function (creatinine 1.04 mg/dL), compensated cirrhosis, and steroid‑induced rise in A1c to 8.0%, which diabetes medications are appropriate for discharge?

Discharge Diabetes Medications for Steroid-Induced Hyperglycemia

This patient should be discharged on metformin plus basal insulin (such as glargine or degludec), with consideration for adding a GLP-1 receptor agonist if weight loss and additional glycemic control are needed. 1

Rationale for Medication Selection

Metformin as Foundation Therapy

Metformin remains the cornerstone first-line agent even in this complex patient 1. Key considerations for this patient:

• Safe with normal renal function: With creatinine 1.04 mg/dL (eGFR clearly >30 mL/min/1.73 m²), metformin is appropriate and carries no contraindication 1
• Cirrhosis is NOT a contraindication: While historically avoided, metformin can be used in compensated cirrhosis with stable liver function tests, which this patient has 1
• Weight neutral to modest weight loss: Important benefit given BMI 35 1
• Cardiovascular mortality benefit: Reduces CV events and death 1

Practical dosing: Start metformin extended-release 500-1000 mg daily with dinner, titrate to 2000 mg daily as tolerated to minimize GI side effects 1

Insulin for Steroid-Induced Hyperglycemia

Given the A1c jump from 6.1 to 8.0 (likely higher actual glycemia due to ongoing dexamethasone), insulin is indicated 1:

• Dexamethasone 20 mg on days 1-2 of each cycle causes significant hyperglycemia, particularly in afternoon/evening
• Basal insulin addresses fasting hyperglycemia and provides foundation control
• Consider rapid-acting insulin for days 1-2 of each chemotherapy cycle when dexamethasone is given

Practical approach:

• Start basal insulin (glargine 10-20 units daily or degludec 10-20 units daily)
• Add mealtime rapid-acting insulin (lispro, aspart, or glulisine) 4-8 units before meals on dexamethasone days
• Titrate based on home glucose monitoring

GLP-1 Receptor Agonist Consideration

A GLP-1 RA should be strongly considered as add-on therapy given this patient's profile 1, 2:

• BMI 35: GLP-1 RAs provide substantial weight loss benefit
• Cardiovascular risk: Obesity and diabetes confer high CV risk; GLP-1 RAs reduce MACE 2
• Cirrhosis/MASLD: GLP-1 RAs have beneficial effects on metabolic-associated steatotic liver disease 1
• Safe with normal renal function: No dose adjustment needed 1

Practical choice: Semaglutide 0.25 mg weekly subcutaneously, titrate to 0.5-1 mg weekly, or dulaglutide 0.75-1.5 mg weekly

Medications to AVOID

Contraindicated or Inappropriate Options:

Sulfonylureas: High hypoglycemia risk, especially with fluctuating steroid doses and potential decreased oral intake during chemotherapy 1

Thiazolidinediones (pioglitazone):

• Contraindicated in cirrhosis due to fluid retention risk
• Weight gain problematic with BMI 35
• Heart failure risk 1

SGLT2 inhibitors: While beneficial for CV/renal outcomes 2, use caution given:

• Cirrhosis (increased DKA risk with hepatic dysfunction)
• Active chemotherapy (infection risk, volume depletion concerns)
• Can consider after chemotherapy completion if clinically stable

Clinical Monitoring Strategy

Key Monitoring Parameters:

• Home glucose monitoring: Fasting and pre-dinner readings daily, plus 2-hour post-meal on dexamethasone days
• Anticipate pattern: Hyperglycemia peaks 8-12 hours after dexamethasone, may persist 2-3 days
• Adjust insulin doses on dexamethasone cycles (may need 2-3x usual doses on days 1-3)
• Monitor vitamin B12 annually on metformin 1
• Recheck A1c in 3 months after glycemic stabilization

Critical Pitfalls to Avoid

1. Underestimating steroid effect: Dexamethasone 20 mg causes profound hyperglycemia; don't rely on oral agents alone
2. Forgetting cycle-specific dosing: Insulin needs will fluctuate dramatically with chemotherapy cycles
3. Avoiding metformin unnecessarily: Compensated cirrhosis with stable LFTs is NOT a contraindication
4. Delaying insulin: With A1c 8.0 and ongoing high-dose steroids, insulin is necessary now 1
5. Missing GLP-1 RA opportunity: This patient has multiple indications (obesity, CV risk, potential MASLD) 2

Discharge Prescription Summary

Immediate discharge medications:

1. Metformin ER 1000 mg once daily with dinner (titrate to 2000 mg over 2-4 weeks)
2. Insulin glargine 15 units subcutaneously at bedtime (titrate by 2 units every 3 days to fasting glucose 100-130 mg/dL)
3. Insulin lispro 6 units before meals on dexamethasone days (days 1-2 of each cycle)
4. Consider adding semaglutide 0.25 mg weekly after 2-4 weeks if tolerating metformin

Follow-up: Endocrinology or diabetes educator within 1-2 weeks for insulin titration and diabetes self-management education, particularly regarding cycle-specific adjustments 1